Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 923 results for "sanofi"

210 images for sanofi

American Banking News, 4 days ago
4 Traders, 6 days ago
Orlando Sentinel, 1 week ago
XinMsn, 1 week ago
XinMsn, 1 week ago
Bio Spectrum Asia, 1 week ago
Yahoo! News, 1 week ago
Bio Spectrum Asia, 1 week ago
Reuters UK, 1 week ago
Business Recorder, 1 day ago
American Banking News

Sanofi-Aventis Makes a Move: Up 1.2%

Sanofi-Aventis (NYSE:SNY) is one of today's notable stocks on the rise, up 1.2% to $56.86. The Dow is trading fractionally higher to 17,134 and the S&P is currently trading fractionally lower
 Individual.com3 hours ago Sanofi-Aventis: 52-Week High Recently Ec...  Financial News Network online46 minutes ago Watch for Continued Gains in Shares of Sanofi-Aventis (SNY)  Comtex SmarTrend2 days ago Sanofi SA Reaches New 1-Year High at $55.99 (SNY)  American Banking News1 week ago

FDA Approves Use of Menactra® Vaccine for Booster Immunization Against Potentially Deadly Disease

By a News Reporter-Staff News Editor at Biotech Week -- Sanofi Pasteur , the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced that the U.S. Food and Drug Administration (FDA) approved use of Menactra(®) [Meningococcal (Groups A, ...
 4 Traders34 minutes ago At Four Years, Treatment Effect Maintained in More Than Two-Thirds of Patients Who Received Genzyme's Lemtrada in Pivotal Studies  4 Traders4 hours ago FDA News Roundup: Astellas, Sanofi Pasteur, Orexigen, and More  Pharmaceutical Online1 day ago FDA Approves Sanofi's Menactra Vaccine  PharmaAsia3 days ago
[x]  

Sanofi, MyoKardia Ink Up to $200M Cardiomyopathies Collaboration

Sanofi will join with MyoKardia to discover and develop targeted therapies for genetic cardiomyopathies based on research by the precision medicine biotech, in a deal that could generate up to $200 million for MyoKardia, the companies said today. ...
 Genetic Engineering News4 hours ago Bay Area Startup MyoKardia Forges $200 Million Heart Disease Pact With Sanofi (France)  BioSpace8 hours ago MyoKardia, Sanofi Ink $200M+ Deal for Targeted Heart Drugs  Xconomy8 hours ago SANOFI : Sanofi and MyoKardia Announce Groundbreaking Collaboration to Develop Targeted Therapies for Patients with Genetic Heart Disease  4 Traders16 hours ago
[x]  

Sanofi: Stiff Competition Will Impact Future Performance

Summary Eli Lilly and Boehringer Ingelheim's biosimilar version of Lantus has been approved by the EMA under the market name of Abasria. Abasria has received tentative approval in the US but will be held off until 2016 due to the lawsuit filed by ...
 Seeking Alpha5 hours ago Biocon up 3% post Mylan's phase-3 trials for Glargine  Moneycontrol.com13 hours ago Eli Lilly Gets EC Approval For Biosimilar Version Of Sanofi's Lantus  Bidness Etc6 days ago EU clears Eli Lilly, Boehringer Ingelheim's biosimilar version of Sanofi's Lantus  FirstWord Pharma1 week ago

Sanofi Partners With US-Based Startup For Genetic Heart Disease Drugs

Sanofi will be collaborating with two-year-old startup MyoKardia for research and development of therapies to treat individuals suffering from genetic heart disease Page 1 of 2 Click Ticker to See live coverage Sanofi SA (ADR) ( SNY ) ...
 Bidness Etc9 hours ago Sanofi unveils heart disease partnership with MyoKardia  Reuters16 hours ago Sanofi, MyoKardia partner to develop targeted therapeutics for heritable heart diseases  News-Medical.Net3 hours ago
[x]  

Potential Sanofi (SNY) Trade Targets 3.42% Return

The patented option trade-picking algorithms behind MarketIntelligenceCenter.com's Artificial Intelligence Center have selected a covered call trade on Sanofi-Aventis (http://www.marketintelligencecenter.com/symbol/SNY"SNY) that includes 5.34% ...
 Individual.com4 hours ago Potential Sanofi (SNY) Trade Has 3.68% Downside Protection  Individual.com5 days ago

Sanofi Still Ahead Of Novo Nordisk In Insulin Drug Race

Novo Nordisk announced positive results yesterday, from the YOUNG trial of its insulin therapy Tresiba. However, Sanofi is still ahead with its blockbuster drug Toujeo Page 1 of 2 Click Ticker to See live coverage Novo Nordisk A/S ...
 Bidness Etc5 hours ago Novo's next-gen insulin clears a pediatric hurdle amid renewed U.S. hope  FierceBiotech1 day ago

Sanofi Wants to Add Oral GLP-1 to Diabetes Offering

Sanofi (SAN) wants to add an oral diabetes drug that mimics a hormone known as GLP-1 as the French drugmaker seeks to lower its reliance on the blockbuster Lantus insulin, set to lose patent protection soon. "It's one of our strategic interests," ...
 BusinessWeek13 hours ago Looming Patent Deadline Pushes Sanofi (France) To Be More Aggressive; Wants To Add Oral GLP-1 To Diabetes Offering  BioSpace8 hours ago Sanofi looks to bolster diabetes portfolio with oral GLP-1 therapy: report  FirstWord Pharma11 hours ago

Partner Sanofi wants to produce the insulin to be used in MannKind's Afrezza

, to buy €120.1 million ($155.7 million) worth of recombinant human insulin from Amphastar France Pharmaceuticals to fill its inhalers. After 11 days, it signed a global marketing agreement with Sanofi ($SNY) for the newly approved Afrezza. Now ...
 FiercePharmaManufacturing3 hours ago Sanofi, MannKind agree licensing deal for Afrezza  Economic Times1 month ago Sanofi, MannKind Corp agree licensing deal for Afrezza insulin  Economic Times1 month ago Asia Pacific insulin market is expected to reach more than USD 10 Billion by 2018  MENAFN1 day ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less